Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.59 |
| ▸ | MAOA | P21397 | 4/20 | 0.59 |
| ▸ | CALML3 | P27482 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613535 | 1.00 | MAOB (0.59) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6111262 | 1.00 | MAOB (0.59) | MAOBMAOACALML3LMNAPTGS1 | |
| Hydrochloric Acid SCHEMBL7850758 | 0.95 | MAOB (0.54) | MAOBMAOACALML3LMNAPTGS1 | |
| Hydrochloric Acid SCHEMBL7850762 | 0.95 | MAOB (0.54) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL80077 | 0.91 | MAOB (0.58) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL3396418 | 0.91 | MAOB (0.58) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL2087746 | 0.90 | MAOB (0.51) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5810297 | 0.89 | MAOB (0.58) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5412271 | 0.89 | MAOB (0.56) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL2507042 | 0.88 | MAOA (0.47) | MAOBMAOACALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759351-B2 | Oxazolidinone compounds, and compositions and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-20 | — | — | US | disclosed |
| EP-1902050-B1 | OXAZOLIDINONE DERIVATIVES AND USE THEREOF AS ANTIBIOTICS | FERRER INT (ES) | 2009-09-09 | — | — | EP | disclosed |
| US-20090062266-A1 | OXAZOLIDINONE COMPOUNDS, AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2009-03-05 | — | — | US | disclosed |
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | FERRER INTERNACIONAL S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| EP-1902050-A1 | OXAZOLIDINONE DERIVATIVES AND USE THEREOF AS ANTIBIOTICS | FERRER INTERNACIONAL, S.A. (ES) | 2008-03-26 | — | — | EP | disclosed |
| US-20070167414-A1 | Novel antibacterial agents | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-07-19 | — | — | US | disclosed |
| EP-1786805-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
| US-7217726-B2 | Antibacterial agents | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-05-15 | — | — | US | disclosed |
| EP-1745784-A1 | Oxazolidinone derivatives and use thereof as antibiotics | FERRER INTERNACIONAL, S.A. (ES) | 2007-01-24 | — | — | EP | disclosed |
| WO-2007000432-A1 | OXAZOLIDINONE DERIVATIVES AND USE THEREOF AS ANTIBIOTICS | FERRER INTERNACIONAL, S. A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006010756-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S. A. (ES) | 2006-02-02 | — | — | WO | disclosed |
| EP-1578734-A1 | NOVEL ANTIBACTERIAL AGENTS | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-09-28 | — | — | EP | disclosed |
| US-20050070526-A1 | Novel antibacterial agents | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2005-03-31 | — | — | US | disclosed |
| WO-2004018439-A1 | NOVEL ANTIBACTERIAL AGENTS | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167414-A1 | Novel antibacterial agents | TBCD, OXA1L, ALPI | MAOB 1771/4885MAOA 1590/4885CALML3 2397/4885 |
| US-20090062266-A1 | OXAZOLIDINONE COMPOUNDS, AND COMPOSITIONS AND METHODS RELATED THERETO | MAOA, MAOB, AOC2 | MAOB 2/4885MAOA 1/4885CALML3 2764/4885 |
| US-20050070526-A1 | Novel antibacterial agents | TBCD, OXA1L, ALPI | MAOB 1771/4885MAOA 1590/4885CALML3 2397/4885 |
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | OXA1L, MAOA, NR0B1 | MAOB 8/4885MAOA 2/4885CALML3 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.